Literature DB >> 15476270

The tumour suppressor gene CEACAM1 is completely but reversibly downregulated in renal cell carcinoma.

Robert Kammerer1, Rainer Riesenberg, Christoph Weiler, Jens Lohrmann, Julia Schleypen, Wolfgang Zimmermann.   

Abstract

CEACAM1 acts as a tumour suppressor in various epithelial tumours. On the other hand, de novo expression of CEACAM1 is strongly associated with reduced disease-free survival of melanoma and non-small cell lung carcinoma patients. Since effector functions of natural killer and T cells are inhibited by homophilic CEACAM1 interaction, immune escape could be responsible for the poor prognosis of these patients. Here, we describe CEACAM1 expression in normal kidney, renal adenomas and renal cell carcinomas (RCC) using a novel antibody generated by genetic immunization. In normal kidney, CEACAM1 was found in epithelial cells of proximal tubules and in endothelial cells. In contrast, tumour cells of 30 clear cell, three chromophobic, and two chromophilic RCCs were completely devoid of CEACAM1. Renal adenomas also lacked CEACAM1 expression. Similarly, RCC cell lines CaKi1, CaKi2, A498, and RCC26 exhibited no or low-level CEACAM1 expression. However, CEACAM1 expression was transiently induced in A498 cells upon contact with allogeneic CD8+ T cells, mediated at least in part by interferon-gamma. Furthermore, the majority of tumour-infiltrating T and NK cells expressed CEACAM1 upon stimulation. Thus, transient expression of the tumour suppressor CEACAM1 by tumour cells and subsequent homophilic interaction with CEACAM1 on tumour-infiltrating lymphocytes could represent a novel immune escape mechanism in RCC. Copyright (c) 2004 Pathological Society of Great Britain and Ireland.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15476270     DOI: 10.1002/path.1657

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  19 in total

1.  [Research in urologic university clinics. Assessment of current status and perspectives].

Authors:  K Miller; H Krause
Journal:  Urologe A       Date:  2006-09       Impact factor: 0.639

2.  The possible roles of OPN-regulated CEACAM1 expression in promoting the survival of activated T cells and the apoptosis of oral keratinocytes in oral lichen planus patients.

Authors:  Gui-Xiang Liu; Qi Xie; Cheng-Jun Zhou; Xiao-Ying Zhang; Bo-Long Ma; Cheng-Qin Wang; Feng-Cai Wei; Xun Qu; Shan-Zhen Sun
Journal:  J Clin Immunol       Date:  2011-06-14       Impact factor: 8.317

3.  CEACAM1 in cervical cancer and precursor lesions: association with human papillomavirus infection.

Authors:  Benibelks Albarran-Somoza; Ramon Franco-Topete; Vidal Delgado-Rizo; Felipe Cerda-Camacho; Lourdes Acosta-Jimenez; Miguel Lopez-Botet; Adrian Daneri-Navarro
Journal:  J Histochem Cytochem       Date:  2006-08-21       Impact factor: 2.479

4.  Loss of mammal-specific tectorial membrane component carcinoembryonic antigen cell adhesion molecule 16 (CEACAM16) leads to hearing impairment at low and high frequencies.

Authors:  Robert Kammerer; Lukas Rüttiger; Rainer Riesenberg; Constanze Schäuble; Rosemarie Krupar; Annegret Kamp; Kishiko Sunami; Andreas Eisenried; Martin Hennenberg; Fritz Grunert; Andreas Bress; Sebastiano Battaglia; Heinrich Schrewe; Marlies Knipper; Marlon R Schneider; Wolfgang Zimmermann
Journal:  J Biol Chem       Date:  2012-04-27       Impact factor: 5.157

Review 5.  The role of CEA-related cell adhesion molecule-1 (CEACAM1) in vascular homeostasis.

Authors:  Uwe Rueckschloss; Stefanie Kuerten; Süleyman Ergün
Journal:  Histochem Cell Biol       Date:  2016-09-30       Impact factor: 4.304

6.  Dynamic expression of protective CEACAM1 on melanoma cells during specific immune attack.

Authors:  Gal Markel; Rachel Seidman; Yifat Cohen; Michal J Besser; Tali Cohen Sinai; Avraham J Treves; Arie Orenstein; Raanan Berger; Jacob Schachter
Journal:  Immunology       Date:  2008-06-13       Impact factor: 7.397

7.  Carcinoembryonic antigen related cell adhesion molecule 6 promotes the proliferation and migration of renal cancer cells through the ERK/AKT signaling pathway.

Authors:  Rujian Zhu; Jiong Ge; Junjie Ma; Junhua Zheng
Journal:  Transl Androl Urol       Date:  2019-10

8.  Integrase-derived peptides together with CD24-targeted lentiviral particles inhibit the growth of CD24 expressing cancer cells.

Authors:  Shiran Shapira; Eynat Finkelshtein; Dina Kazanov; Esmira Naftali; Irena Stepansky; Abraham Loyter; Daniel Elbirt; Mori Hay-Levy; Eli Brazowski; Faina Bedny; Roy Dekel; Dov Hershkovitz; Arye Blachar; Ido Wolf; Nadir Arber
Journal:  Oncogene       Date:  2021-05-06       Impact factor: 9.867

9.  Clinical and experimental studies regarding the expression and diagnostic value of carcinoembryonic antigen-related cell adhesion molecule 1 in non-small-cell lung cancer.

Authors:  Mu-qing Zhou; Yan Du; Yi-wen Liu; Ying-zhi Wang; Yi-qing He; Cui-xia Yang; Wen-juan Wang; Feng Gao
Journal:  BMC Cancer       Date:  2013-07-25       Impact factor: 4.430

10.  Disturbed expression of splicing factors in renal cancer affects alternative splicing of apoptosis regulators, oncogenes, and tumor suppressors.

Authors:  Agnieszka Piekielko-Witkowska; Hanna Wiszomirska; Anna Wojcicka; Piotr Poplawski; Joanna Boguslawska; Zbigniew Tanski; Alicja Nauman
Journal:  PLoS One       Date:  2010-10-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.